Starting October 1, 2026, the executive officer system will be introduced. The CEO will be the chief operating officer, with multiple executive officers appointed and currently held positions concurrently, and restricted stock units will be granted as compensation.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Kringle Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-16","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4884-20260916-01.pdf","jir_short_summary":"Starting October 1, 2026, the executive officer system will be introduced. The CEO will be the chief operating officer, with multiple executive officers appointed and currently held positions concurrently, and restricted stock units will be granted as compensation.","jir_summary":"### Purpose of Introduction\nThis notice, published today, aims to establish an executive officer system to clearly delineate functions and authority across research and development, manufacturing, and business development in anticipation of progress in development stages and overseas expansion, enabling swift and agile execution. The CEO will be positioned as the top executive officer, and the company will strengthen its management foundation and enhance corporate value.\n\n### Human Resources Structure and Timing\nAppointment and dismissal of executive officers are determined by the board of directors, terms are one year with the possibility of reappointment, and directors may concurrently serve as executive officers. The CEO will be the overall supervisor, and compensation will be granted in the form of restricted stock. The introduction date is October 1, 2026. As of the executive officer appointments on October 1, 2026, Kiichi Adachi will serve as CEO and Representative Director President, Koichi Murakami as Executive Officer General Affairs Head, Taima Hayata as Executive Officer Head of Pharmaceutical Development and Chief Pharmacist, Yoshiyuki Chino as Executive Officer Head of Reliability Assurance, and Kazuaki Kinjo as Head of the Corporate Strategy Office.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#KringlePharma, #ExecutiveOfficerSystem, #ExecutiveAppointments","jir_key_figures":"Executive Officer System Introduction Resolution Date: 2026-09-16 (document date)\nTiming of introduction: 2026-10-01\nNewly appointed executive officers: Kiichi Adachi, Koichi Murakami, Taima Hayata, Yoshiyuki Chino, Kazuaki Kinjo","jir_meta_title":"\u3010KringlePharma\u3011Notice of Introduction of the Executive Officer System | September 16, 2026","jir_meta_description":"KringlePharma resolved to introduce the executive officer system on September 16, 2026. CEO designated as the top executive, and executive officers with one-year terms appointed. Implementation starts October 1.","jir_og_title":"Introduction of the Executive Officer System at KringlePharma","jir_og_description":"KringlePharma introduces the executive officer system. The CEO will oversee as the chief executive, and personnel changes will be implemented as of October 1, 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-114589","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n